Is Macleods Pharmaceuticals planning an IPO?

Macleods Pharmaceuticals has been among the most frequently discussed pharma IPO candidates in India. As of available information, the company has explored listing options but has not finalised a definitive IPO timeline.

Who are the promoters of Macleods Pharmaceuticals?

The company is promoted by the Rajgor family, primarily Rajesh Rajgor and other family members including Bansi Rajgor and Bhavesh Rajgor, who have led the company since inception.

What is Macleods Pharmaceuticals known for?

Macleods is particularly known for being one of the world's largest producers of anti-tuberculosis (anti-TB) drugs. It also has a strong portfolio of branded generics and is a significant exporter to regulated and semi-regulated markets.

Does Macleods Pharmaceuticals export its products?

Yes. Macleods exports to over 100 countries including highly regulated markets in the US and Europe. Exports constitute a significant portion of total revenue.

What is the approximate revenue of Macleods Pharmaceuticals?

Macleods Pharmaceuticals has reported revenues in the range of ₹5,000–6,000 crore in recent years, making it one of India's largest private pharma companies.

How do I buy Macleods Pharmaceuticals unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Macleods Pharmaceuticals?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Macleods Pharmaceuticals shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Macleods Pharmaceuticals Unlisted Share Price | Buy Macleods Pharmaceuticals Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

Macleods Pharmaceuticals Unlisted Share Price | Buy Macleods Pharmaceuticals Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

Macleods Pharmaceuticals Limited is one of India's most significant unlisted pharmaceutical companies, with revenues of approximately ₹5,000–6,000 crore, global export presence in 100+ countries, and world-leading anti-TB drug manufacturing capabilities. Promoted by the Rajgor family since 1989, the company represents a rare opportunity to invest in a large, profitable private pharma business. A future IPO remains a key potential catalyst for value realisation.

Pros

One of India's top 10 pharmaceutical companies by revenue with annual revenues exceeding ₹5,000 crore
Strong international presence with product registrations in over 100 countries including regulated markets like the US, Europe, and Australia
Diversified product portfolio spanning generics, APIs, anti-TB drugs, and specialty pharmaceuticals
Largest global supplier of anti-tuberculosis (anti-TB) drugs with significant WHO and government supply contracts
Vertically integrated operations from API manufacturing to finished dosage forms reducing dependence on external suppliers
Strong promoter commitment with Rajgor family holding majority stake and active management involvement
USFDA-approved manufacturing facilities ensuring quality compliance for export markets

Cons

Unlisted status limits liquidity for shareholders and restricts access to public capital markets for expansion
Dependent on regulated markets (US, EU) which carry USFDA and EMA inspection risk
Concentration in anti-TB segment creates vulnerability to WHO procurement policy changes
Generic pharmaceutical margins are under pressure globally due to pricing competition
Large private pharmaceutical companies face scrutiny over related-party transactions and governance
Currency risk on export revenues which constitute a large portion of total revenue

Business Segments

Branded Generics — Domestic

Marketing and distribution of branded generic pharmaceuticals across therapeutic areas including cardiology, diabetology, anti-infectives, and gastroenterology in the Indian market.

International Generics & Export

Export of generic finished dosage formulations to regulated markets (US, EU, Australia) and semi-regulated markets in Africa, Southeast Asia, and Latin America. Includes USFDA-approved products.

Active Pharmaceutical Ingredients (APIs)

Manufacturing and supply of bulk APIs for internal consumption and third-party customers globally. Strong position in anti-TB API supply.

Anti-TB & Global Health

Specialised supply of anti-tuberculosis drugs and other global health medicines under WHO and government procurement programmes.

Revenue Model

Macleods Pharmaceuticals generates revenue through domestic branded generic pharmaceutical sales, export of generic formulations to regulated and semi-regulated international markets, API manufacturing and supply, and specialised anti-TB drug procurement contracts with governments and international organisations. The company benefits from a vertically integrated model where API manufacturing supports both export formulations and domestic branded sales.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds14

Growth Plans

Potential IPO listing that would provide price discovery and significant value unlocking for promoters and shareholders

US generics market: ongoing ANDA approvals expanding the US product portfolio and revenue base

Growing demand for generic medicines globally driven by patent cliffs of branded drugs

India's domestic pharma market growth driven by rising healthcare spending and insurance coverage

Recent Developments

Continued US ANDA Pipeline Expansion

Macleods continued filing Abbreviated New Drug Applications (ANDAs) with USFDA for the US generics market, expanding its portfolio in cardiology, CNS, and anti-infective segments.

2023-06

Strong Export Growth

The company reported continued strong export growth to regulated markets in the US and Europe, driven by a diversified USFDA-approved product basket.

2023-09

IPO Speculation Continues

Industry sources continued to discuss Macleods Pharmaceuticals as a likely IPO candidate given its scale and profitability, though no formal DRHP was filed as of available information.

2024-03

Comparable Companies

CompanyTypeTickerMkt Cap

Sun Pharmaceutical IndustriesListedSUNPHARMA~₹3,50,000 Cr

Cipla LimitedListedCIPLA~₹1,20,000 Cr

Lupin LimitedListedLUPIN~₹80,000 Cr

Sun Pharmaceutical IndustriesListed

SUNPHARMA · ~₹3,50,000 Cr

Frequently Asked Questions

About Macleods Pharmaceuticals

Macleods Pharmaceuticals Limited is one of India's largest privately-held pharmaceutical companies, incorporated on 5 June 1989. Headquartered in Mumbai with over 22,944 employees as of October 2024, Macleods is a fully integrated pharmaceutical company spanning APIs (Active Pharmaceutical Ingredients), generic formulations, and specialty medicines sold across India and exported to regulated markets globally. The company reported revenue of INR 9,670 crore for the financial year ending March 31, 2025 — placing it among India's top 10 pharmaceutical companies by revenue. Revenue grew 10.53% in FY2024, while profit improved 38.69% in the same year, indicating significant margin expansion and operational maturity. CARE Ratings has formally rated Macleods Pharmaceuticals, citing as key strengths: the company's dominant position in the domestic formulations market, diversified product portfolio spanning multiple therapeutic segments, wide marketing and distribution network, strong product pipeline, healthy capital base, and minimum reliance on external debt leading to comfortable leverage and debt coverage indicators. These factors collectively support a strong investment-grade credit profile. Macleods' therapeutic areas include anti-infectives (antibiotics, antifungals), anti-tuberculosis, cardiovascular, metabolic/diabetic, respiratory, and specialty dermatology segments. The company serves the Indian domestic market through a large salesforce and exports to over 100 countries including regulated markets in the US, Europe, and Australia. The company's international regulated-market access — particularly US FDA-approved facilities — differentiates it from purely domestic generics players. Macleods has received US FDA clearances for multiple API and formulation manufacturing sites, enabling it to compete in the high-value US generics market. A potential IPO has been discussed in financial circles, which would make Macleods one of the largest pharma IPOs in India given its scale.

Key Milestones

Common questions about unlisted shares

How do I buy Macleods Pharmaceuticals unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Risk factors & red flagsInvestment risks and items flagged from public filings13

Fraud / GovernanceLow

USFDA and EMA inspections of manufacturing facilities can lead to import alerts or warning letters, disrupting export revenue from regulated markets

Source: Company Financial Filings

Fraud / GovernanceLow

Generic pharmaceutical pricing in the US market has been under sustained deflation; increased competition from Indian and Chinese generics manufacturers compresses margins

Source: Company Financial Filings

Business ScaleLow

Large export revenue base creates significant exposure to USD/INR and other currency movements; rupee appreciation can reduce export realisation

Source: Company Financial Filings

Fraud / GovernanceLow

Significant dependence on anti-TB drug segment where revenue is tied to government/WHO procurement, which can be subject to policy or budget changes

Source: Company Financial Filings

Fraud / GovernanceLow

Family-owned private company; leadership succession and corporate governance standards may not match publicly listed peers

Source: Media Reports / Public Records

Operational RiskLow

Profitability susceptible to fluctuation in foreign exchange rate

Source: AlphaHub Research

Fraud / GovernanceMedium

Inherent regulatory risk associated with the pharmaceutical industry

Source: Media Reports / Public Records

Operational RiskLow

Applicable criteria

Source: AlphaHub Research

Regulatory

USFDA and EMA inspections of manufacturing facilities can lead to import alerts or warning letters, disrupting export revenue from regulated markets

Pricing Pressure

Generic pharmaceutical pricing in the US market has been under sustained deflation; increased competition from Indian and Chinese generics manufacturers compresses margins

Currency Risk

Large export revenue base creates significant exposure to USD/INR and other currency movements; rupee appreciation can reduce export realisation

Concentration Risk

Significant dependence on anti-TB drug segment where revenue is tied to government/WHO procurement, which can be subject to policy or budget changes

Succession & Governance

Family-owned private company; leadership succession and corporate governance standards may not match publicly listed peers

Macleods Pharmaceuticals Limited

How settlement works

Get price alerts for Macleods Pharmaceuticals Limited

Discuss Macleods Pharmaceuticals

Similar companies

Other ways to invest